Can incorporating genotyping data into efficacy estimators improve efficiency of early phase malaria vaccine trials?

Table 3 Power estimated by resampling smaller trials from the RTS,S data

Control arm event rate	Vaccine arm event rate	Sample size	VE_HR power	VE_C power
0.38	0.26	80	0.29	0.33
0.38	0.26	150	0.52	0.56
0.38	0.26	250	0.75	0.78
0.60	0.30	80	0.85	0.80

The first three rows show estimated power from direct resamples of the RTS,S data. The fourth row shows power from an artificially imposed higher control group event rate and larger risk ratio reduction but matches the mean clones and time-to-even distributions among infected participants in each group. Because time-to-event distributions match only those among infected RTS,S participants but fewer people escape infection than in the RTS,S data, the hazard ratio for the fourth row does not match that in the RTS,S data

ISSN: 1475-2875